Journal of Leukocyte Biology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published online as doi:10.1189/jlb.0604373 on December 6, 2004

Published online before print December 6, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.0604373v1
77/3/378    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jahrsdörfer, B.
Right arrow Articles by Weiner, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jahrsdörfer, B.
Right arrow Articles by Weiner, G. J.
(Journal of Leukocyte Biology. 2005;77:378-387.)
© 2005 by Society for Leukocyte Biology

Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells

Bernd Jahrsdörfer*, James E. Wooldridge*,{dagger}, Sue E. Blackwell*, Christiana M. Taylor*, Thomas S. Griffith*,{ddagger}, Brian K. Link*,{dagger} and George J. Weiner*,{dagger},1

* The Holden Comprehensive Cancer Center and Departments of
{dagger} Internal Medicine and
{ddagger} Urology, University of Iowa, Iowa City

1 Correspondence: Holden Cancer Center at The University of Iowa, 5970Z JPP, University of Iowa, Iowa City, IA 52242. E-mail: george-weiner{at}uiowa.edu


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Immunostimulatory oligodeoxynucleotides (IS ODN) can mediate a number of immunologic effects. We previously demonstrated that treatment of B cell chronic lymphocytic leukemia (B-CLL) cells with one class of IS ODN, CpG ODN, alters their phenotype and increases their immunogenicity. Here, we demonstrate that in contrast to the classic understanding of CpG ODN as inhibitors of B cell apoptosis, IS ODN including CpG ODN induce apoptosis in B-CLL cells. It is important that these changes are seen not only with CpG ODN but with ODN that lack the classical CpG motif. B-CLL cells from 20 subjects were treated in vitro with IS ODN for up to 7 days. IS ODN treatment resulted in increased numbers of apoptotic cells in 13 out of 20 B-CLL samples. IS ODN enhanced apoptosis in samples with 13q deletion as a single aberration and had a heterogeneous effect on apoptosis in samples with other aberrations including 17p deletion, 11q deletion, or trisomy 12. Induction of apoptosis did not correlate with expression of the CpG ODN receptor Toll-like receptor 9. Apoptosis was dependent on the activation of caspases and was accompanied by up-regulation of CD95/Fas and its ligand. We conclude that IS ODN including CpG ODN can induce apoptosis of most B-CLL samples. The ability of IS ODN to induce apoptosis differs based on cytogenetic status. Up-regulation of CD95/Fas may play a role in IS ODN-induced apoptosis of B-CLL.

Key Words: B-CLL • cytogenetic status • CpG ODN • caspase


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
B cell chronic lymphocytic leukemia (B-CLL), the most common leukemia in the western hemisphere, is a heterogeneous B cell malignancy characterized by an imbalance between proliferation and apoptosis and hence, the progressive accumulation of CD5+ B cells in peripheral blood, secondary lymphoid tissue, and bone marrow [1 ]. Recently, the presence of distinct chromosomal aberrations within the malignant B cell population has been shown to correlate strongly with clinical prognosis, disease progression, and treatment-free interval [2 ]. The most frequent aberration is 13q deletion, found in B-CLL cells in up to 50% of patients. Patients with 13q deletion have a relatively good clinical prognosis and exhibit the longest median treatment-free interval among B-CLL patients (92 months), and nearly one-third of them do not require therapy at all. In contrast, patients with 17p and 11q deletions or trisomy 12 hold significantly shorter median treatment-free intervals (9, 13, and 33 months, respectively) and have a worse clinical prognosis.

In recent years, an increasing interest in immunotherapeutic strategies for the treatment of B cell malignancies such as B-CLL has developed. B cell malignancies, including B-CLL, are poorly antigenic [3 , 4 ]. Different approaches have begun to explore whether it is possible to overcome this obstacle by up-regulating costimulatory and antigen-presenting molecules. Strategies tested include the application of cytokines, CD40 ligation, and the use of immunostimulatory oligodeoxynucleotides (IS ODN) including CpG-containing ODN (CpG ODN) [3 , 5 6 7 8 9 10 11 12 ]. Previous data from our group and others have demonstrated that IS ODN are capable of inducing a change in phenotype of normal and malignant B cells, which would be expected to increase their immunogenicity [9 , 12 , 13 ]. IS ODN are also able to induce proliferation and protection from apoptosis in healthy B cells, thus providing a potential explanation for the expansion of B cells in response to invading pathogens in vivo [13 , 14 ].

We recently showed that the B-CLL cell-proliferative response to IS ODN is low compared with normal B cells [9 ]. In the studies outlined below, we demonstrate that various IS ODN can actually induce B-CLL apoptosis in most but not all samples and explore the potential mechanisms responsible for this effect.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Patients and cell culture
Peripheral blood from four healthy subjects and 20 subjects with B-CLL were used for this study. The diagnosis of B-CLL required persistent lymphocytosis (>5000 lymphocytes per cubic mm). Immunophenotypic data showed that all the cases of leukemia were CD19+ CD5+. B-CLL subjects were not under treatment at the time the samples were obtained. Informed consent was obtained from each subject. Peripheral blood mononuclear cells (PBMC) were isolated as described previously [15 ], and red blood cells were removed by resuspending the cells in 5 ml red cell lysis buffer according to standard procedures. In some experiments, CD19+ B-CLL cells were magnetically purified using an untouched B cell isolation kit according to the manufacturer’s instructions (Miltenyi Biotec, Auburn, CA). In these experiments, purity of CD19+ cells after isolation was >99%, and the frequency of plasmacytoid dendritic cells (DC) as detected by blood DC antigen (BDCA)-2 and lineage 1 cocktail (BD Biosciences, San Diego, CA) was <0.006%. For in vitro culture, cells were suspended in RPMI 1640 (Gibco BRL, Grand Island, NY) supplemented with 10% heat-inactivated (56°C) fetal calf serum (FCS; HyClone, Logan, UT), 1.5 mM L-glutamine (Gibco BRL), 100 U/ml penicillin, and 100 µg/ml streptomycin (complete medium) at a concentration of 1 x 106/ml. Cells were then incubated in 96-well plates (1x106 cells/ml, 200 µl/well) in the presence or absence of ODN as indicated. In some experiments, fusion proteins consisting of the Fc portion of human immunoglobulin (Ig) and Fas, tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2, or a control protein (Alexis Biochemicals, San Diego, CA) at 5 µg/ml were added during the whole culture period.

ODN
Nuclease-resistant phosphorothioate (PS)-modified ODN were provided by the Coley Pharmaceutical Group (Wellesley, MA). Endotoxin levels in all ODN were <0.075 EU/ml by limulus amebocyte lysate assay. As control ODN, we used a non-IS ODN (ODN 2243). Specific sequences were as follows: IS ODN with CpG motif and PS backbone: ODN 2006-5'-TCG TCG TTT TGT CGT TTT GTC GTT-3'; IS ODN with methylated CpG motif and PS backbone: ODN 2117-5'-TCG TCG TTT TGT CGT TTT GTC GTT-3'; IS ODN without CpG motif and PS backbone: ODN 2137-5'-TGC TGC TTT TGT GCT TTT GTG CTT-3'GC; IS ODN with CpG motif and phophodiester backbone: ODN 2059-5'-TCG TCG TTT TGT CGT TTT GTC GTT-3'; control ODN with mixed PS/phosphodiester (PO) backbone: ODN 2243-5'-GGG GGA GCA TGC TGG GGG GG-3'.

Underlined nucleotides have PS linkages at their 3'-ends; all others have PO linkages. ODN were diluted in 10 mM Tris-HCl, 1 mM EDTA, pH 8, using pyrogen-free reagents. If not otherwise stated, the IS ODN used in this study was ODN 2006. The controls included medium only or ODN 2243.

Phenotypic determination
At the time-points indicated, cells were washed in ice-cold phosphate-buffered saline (PBS) and stained for expression of various antigens. For surface staining, 2 x 105 cells per sample were stained with fluorescently labeled monoclonal antibodies (mAb), which against CD5 [phycoerythrin (PE), UCHT2], CD19 (Cy-Chrome, HIB19), Fas (PE, DX2), Fas ligand (biotin, NOK-1), CD54 (PE, HA58), CD80 (PE, L307.4), and CD86 (PE, FUN-1) as well as appropriate isotype controls were purchased from BD Biosciences. For intracellular staining of {zeta}-associated protein-70 (ZAP-70), 2 x 105 cells were fixed and permeabilized per the manufacturer’s protocol (Fix and Perm, Caltag, South San Francisco, CA). Briefly, cells were washed with PBS (400 g, 4°C, 5 min), incubated for 15 min with fixation buffer A, washed again, and then incubated with permeabilization buffer B, together with 10 µl PE-labeled anti-ZAP-70 mAb (1E7.2, eBioscience, San Diego, CA) or the corresponding isotype control antibody. Cells were then washed twice (400 g, 4°C, 5 min), resuspended in PBS, and immediately analyzed by flow cytometry using a FACScan (Becton Dickinson Immunocytometry Systems, San Jose, CA). Spectral overlap was corrected by appropriate compensation. For surface-staining experiments, viable cells were gated according to their typical forward-/side-scatter (FSC/SSC) characteristics and propidium iodide (PI) staining. Data were analyzed with the fluorescein-activated cell sorter (FACS) evaluation program FlowJo (version 4.5, Tree Star, Inc., Stanford, CA). Median fluorescence intensity (MFI) values were used for statistical analysis of ZAP-70 and surface marker expression.

Apoptosis and cell survival assays
Cells were harvested at the indicated time-points by staining all the cells from a given well with mAb for a lineage-specific antigen and fluorescein isothiocyanate (FITC)-labeled Annexin V (BD Biosciences) or incubated with a cell-permeable fluorogenic caspase 6 (CyToxiLuxTM, OncoImmunin, Gaithersburg, MD) or caspase 8 substrate (Caspase 8 FLICA, Immunochemistry Technologies LLC, Bloomington, MN) for 1 h, according to the manufacturer’s instructions. A predetermined number of calibration beads (CaliBRITETM Beads, BD Biosciences) were then added to each sample to allow for normalization of cell counts in different samples at different time-points. PI at 1 µg/ml was added just prior to flow cytometric detection. The count of viable cells rather than the count of apoptotic cells was used for the calculation of B-CLL cell survival because of concerns that some nonviable cells may have undergone lysis and not have been available for counting. Absolute cell survival is expressed as percentage of viable cell counts relative to initial plating counts. The absolute cell survival in IS ODN-stimulated samples divided by the cell survival in samples incubated in medium alone is referred to as relative IS ODN survival.

Fluorescence in situ hybridization (FISH)
Unstimulated PBMC from subjects with B-CLL were cultured for 24 h in RPMI-media containing 15% FCS and antibiotics. Slides were made after the cells had been processed and fixed in 3:1 methanol and acetic acid fixative. The FISH studies were performed using a CLL probe panel (VYSIS, Downers Grove, IL), which includes two cocktail probes. One set contains ATM (11q22.3)/17p13.1 (p53), and the second set has 12cen (CEP12)/13q14.3 (D13S319)/13q34. These studies were carried out using standard methods as specified by the manufacturer. Three hundred interphase nuclei were analyzed for each probe set. The cutoff for positive values was 2.2% for trisomy 12 and 2.7%, 6.4%, 6.0%, and 4.4% for ATM, p53, D13S319, and 13q34, respectively.

Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for TLR9
For the analysis of Toll-like receptor 9 (TLR9) mRNA expression, B-CLL cells were isolated (>95% CD19+ CD5+) from peripheral blood, and RNA from 10 x 106 cells per sample was prepared using the RNeasy mini kit from Qiagen (Valencia, CA). Total RNA (500 ng) was reverse-transcribed using SuperScript III RNase H-RT (Invitrogen, Carlsbad, CA) in a 20-µl reaction volume. The generated cDNA (3 µl) was used per 25 µl real-time PCR carried out with the Platinum Quantitative PCR SuperMix-UDG kit (Invitrogen). Primers and probes were purchased from Integrated DNA Technologies (Coralville, IA): TLR9 forward: 5'-GCC AGA CCC TCT GGA GAA-3'; TLR9 reverse: 5'-AGA CTT CAG GAA CAG CCA GTT G-3'; TLR9 probe: 5'-/56-FAM/TAC CTT GCC TGC CTT CCT ACC CTG TGA/3BHQ-1/-3'; ß-actin forward: 5'-CAC ACC TTC TAC AAT GAG CTG CGT-3'; ß-actin reverse: 5'-ACA GCC TGG ATA GCA ACG TAC A-3'; ß-actin probe: 5'-FAM/AAC CGC GAG AAG ATG ACC CAG ATC AT/BHQ-3'. The amplification efficiency of the primers was 2.0 ± 10%. The copy number of TLR9 was calculated from a standard curve generated by plotting the log dilutions of known concentrations of a plasmid containing the amplicon versus the cycle threshold values and was normalized by the housekeeping gene ß-actin. TLR9 copy number is presented as number of transcripts per 103 copies of ß-actin.

Statistical analysis
Data are expressed as means ± SEM. To determine statistical differences in the mean of two data columns, the two-sample t-test was used. A P value of <0.05 was considered to be significant; a P value of <0.005 was considered to be highly significant. Statistical analysis was performed using the SAS System for Windows (SAS, version 8.2. 2001, SAS Institute, Cary, NC).


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
B-CLL cells are sensitive to IS ODN-mediated apoptosis
We previously reported that CpG ODN can have pro- and antiapoptotic effects on B-CLL cells when cultured up to 4 days in vitro [10 ]. To evaluate this phenomenon further, we used a slightly modified assay and tested a larger number of B-CLL samples for which we had obtained interphase FISH to assess for common B-CLL-associated chromosomal aberrations (Table 1 ). We also evaluated the effect of IS ODN which lack the CpG motif. B-CLL cells were suspended in complete medium, cultured for up to 7 days in the presence or absence of ODN, and then harvested and stained with Annexin V, CD19 PE, and PI. A set number of calibration beads were added to the samples to provide a basis for determining the number of viable cells and thus comparing survival at different days. Figure 1A shows a typical set of dot-plots from one representative experiment with B-CLL cells. Gating was performed as described in the title legend. In pilot experiments, we determined that apoptosis in response to IS ODN reached a plateau at concentrations above 2.5 µg/ml (Fig. 1B) .


View this table:
[in this window]
[in a new window]
  		Table 1. Clinical Data of B-CLL Patients Included in the Study

 


View larger version (28K):
[in this window]
[in a new window]
  		Figure 1. In vitro B-CLL cell survival in response to ODN. PBMC from subjects with B-CLL were suspended in complete medium and cultured on 96-well plates at 37°C in the presence of different ODN at concentrations as indicated. On day 4, cells were harvested, and the number of viable B-CLL cells was determined by Annexin V/PI staining. (A) Bead counts were used to normalize viable B-CLL cell counts. The top plot shows the gating on the calibration beads and total mononuclear cells and the middle plot, gating on the CD5+, CD19+ cell subset. (B) Survival of IS ODN-sensitive B-CLL cells in response to different ODN at increasing concentrations. Data are from one representative experiment out of three with similar results.

 
As illustrated in Figure 1B , CpG ODN and non-CpG IS ODN had effects on B-CLL cells. CpG ODN 2006, ODN 2117, which has a methylated CG, and ODN 2137, which is similar to 2006 but has a GC instead of a CG, all had effects on B-CLL cell survival as well as on normal B cell phenotype (Fig. 1B and own unpublished data). Also the PO CpG ODN 2059 had similar effects on B-CLL cell survival, although higher ODN concentrations were necessary than with PS ODN (Fig. 1B) . ODN 2243, which has recently been described as a control for ODN 2216, had a weak effect on B-CLL cell survival (Fig. 1B) . In addition, ODN 2006, 2117, 2137, and 2059 (at higher concentrations) induced proliferation of benign B cells, and ODN 2243 had a low effect on benign B cell proliferation (own unpublished data). For all subsequent studies, we used medium only or ODN 2243 at 5 µg/ml as controls and ODN 2006 at 5 µg/ml as IS ODN.

A total of 20 different subjects with B-CLL were tested. All B-CLL samples exhibited ≥90% viable cells at day 0. Incubation with IS ODN resulted in lower absolute B-CLL cell survival after 4 and 7 days incubation when compared with samples cultured with control ODN or media (Fig. 2A ; IS ODNday 4, 38±6%; control ODNday 4, 50±7%, *P<0.03; IS ODNday 7, 35±5%; control ODNday 7, 52±7%, **P<0.001). However, as seen in earlier studies with 4-day cultures, B-CLL cell viability in the absence and the presence of IS ODN was heterogeneous. B-CLL cells bearing 13q deletions as a single aberration had a relative IS ODN survival <1 in all nine cases studied; i.e., the B-CLL viability was lower in the presence than in the absence of IS ODN (Fig. 2B , left bar and Table 1 ). In contrast, B-CLL cells with other chromosomal aberrations including 17p deletion, trisomy 12, or 11q deletion responded heterogeneously to IS ODN (Fig. 2B , middle bar and Table 1 ). The difference in relative IS ODN survival between the 13q and the non-13q groups was statistically significant (Fig. 2B ; 13q deletion cells: 0.61±0.09; non-13q deletion cells: 1.18±0.22, *P<0.02). As to be expected, B cells from normal, healthy donors showed proliferation in response to IS ODN and therefore had a relative IS ODN survival >1 (Fig. 2B , right bar).



View larger version (28K):
[in this window]
[in a new window]
  		Figure 2. Effect of IS ODN on B-CLL cell survival. PBMC from 20 subjects with B-CLL and four healthy volunteers were suspended in complete medium and cultured on 96-well plates at 37°C in the presence or absence of 5 µg/ml IS ODN or control ODN. On days 0, 4, and 7, cells were harvested, and the number of viable cells was determined by Annexin V/PI staining. (A) Average survival of B-CLL cells from 20 individuals in the presence or absence of IS ODN or control ODN is compared over time. Error bars indicate SEM. (B) The ratio of the cell count in IS ODN-treated samples to the cell count in nontreated samples is referred to as relative IS ODN survival. Average relative IS ODN survival of B-CLL samples from two cytogenetic groups as well as normal B cells at day 4 is compared. Error bars indicate SEM. Diamonds represent individual data points. (C) Comparison of IS ODN effects on unsorted versus enriched B-CLL cells. PBMC from subjects with IS ODN-sensitive B-CLL cells were isolated as described and magnetically separated from non-B-CLL cells. The frequency of plasmacytoid DC [natural interferon (IFN)-producing cells], as defined by BDCA-2 and lineage 1 staining, was below 0.006% in the enriched samples. Unsorted and enriched samples were suspended in complete medium and cultured on 96-well plates at 37°C in the presence or absence of ODN 2006 at 5 µg/ml for 4 and 7 days. Cells were harvested, and survival was determined based on Annexin V/PI staining and the use of calibration beads as described above. Similar results were obtained in two further experiments with B-CLL cells from different subjects.

 
Further studies were done to evaluate whether the effect of IS ODN was a direct effect on the B-CLL cells or mediated by other cell populations in the samples that might have been activated by IS ODN, particularly the natural IFN-producing cell (plasmacytoid DC), which is directly activated by IS ODN [16 ]. The relative IS ODN survival of B-CLL cells did not correlate with the percentage of non-B-CLL cells present in the samples, which ranged from less than 1% to over 50% (Table 1) . Results were similar when IS ODN were added to B-CLL cells after the malignant cells had been purified by magnetic cell separation (Fig. 2C) . No correlation was detected between relative IS ODN survival and other clinical parameters, including white blood cell count, Rai stage, ZAP-70, and CD38 expression (Table 1 and data not shown).

Degree of IS ODN-mediated apoptosis is not a result of level of TLR9 message or prior therapy
One potential explanation for the observed differences in response to IS ODN between the cytogenetic groups is differential expression of the IS ODN receptor TLR9. Real-time RT-PCR was performed on nine samples to assess for quantitative differences in TLR9 expression between 13q deletion B-CLL cells and other B-CLL cells. No significant differences were identified in TLR9 expression based on cytogenetic status, and there was no correlation between TLR9 message and sensitivity to IS ODN (Fig. 3 ). There was no evidence for correlation between sensitivity of IS ODN-mediated apoptosis and prior therapy (Table 1) .



View larger version (12K):
[in this window]
[in a new window]
  		Figure 3. TLR9 expression in B-CLL cells with different cytogenetic status. PBMC from nine subjects with B-CLL were isolated from peripheral blood. All subjects had >95% CD19+ CD5+ cells. RNA from 106 cells per sample was prepared, and real-time RT-PCR for TLR9 was performed as described in Materials and Methods. TLR9 copy numbers for two prognostically distinct B-CLL groups are presented as number of transcripts per 103 copies of ß-actin.

 
Induction of apoptosis in B-CLL cells by IS ODN is caspase-dependent
We next evaluated whether the ability of IS ODN to induce apoptosis of B-CLL cells was caspase-dependent. This was done using two different methods. The first assay involved detection of caspase 6 and caspase 8 activity; the second was based on suppressing caspase activity by a pan-caspase inhibitor. B-CLL cells were incubated for 1 h with cell-permeable fluorogenic caspase substrates. Fluorescing cells are considered caspase-positive. Figure 4A shows representative histograms demonstrating an increase in caspase-positive cells in samples treated with IS ODN but not with control ODN or medium alone (Fig. 4A) . Similar results were observed for five individual subjects with B-CLL cells sensitive to IS ODN-mediated apoptosis. On day 4, a statistically significant difference in the percentage of caspase 6-negative cells was found between IS ODN-treated and nontreated samples (Fig. 4B) . The difference between IS ODN-treated and control ODN-treated cells was not statistically significant. We also evaluated whether IS ODN-induced apoptosis was decreased by the pan-caspase inhibitor zVAD (50 µM). Figure 4C shows the average of three individual B-CLL samples sensitive to IS ODN-mediated apoptosis. In this experimental series, IS ODN suppressed B-CLL cell survival after 4 days of incubation from 47% (incubation in medium alone) to 30%. zVAD could inhibit this effect by 64%, resulting in a survival of 41% (Fig. 4C ; *P<0.02).



View larger version (33K):
[in this window]
[in a new window]
  		Figure 4. B-CLL cell apoptosis involves caspase activation. PBMC from five subjects with B-CLL were obtained and cultured in the presence or absence of 5 µg/ml IS ODN (ODN 2006) or control ODN (ODN 2243) at 37°C. Caspase activation on days 0, 4, and 7 was determined using cell-permeable, fluorogenic caspase substrates for caspases 8 and 6. (A) Histograms of two representative experiments. The percentages of cells positive for activated caspases are shown. Similar results were observed for five individual subjects with B-CLL cells sensitive to IS ODN-mediated apoptosis. (B) Average percentage of caspase 6-negative B-CLL cells for five individual samples on day 4. (C) PBMC from three subjects with B-CLL were obtained and cultured in the presence or absence of 5 µg/ml IS ODN and 50 µM pan-caspase inhibitor Z-Val-Ala-Asp (zVAD). Survival on day 4 was determined by Annexin V/PI staining. The y-axis represents the percentage of viable (Annexin V/PI-negative) B-CLL cells. Error bars indicate SEM.

 
IS ODN-induced apoptosis in B-CLL cells is accompanied by up-regulation of death receptors and their ligands but cannot be blocked by soluble Fas or TRAIL receptor 2
The finding of caspase-dependent apoptosis, especially activation of caspase 8, points to the possible involvement of death receptors of the TNF receptor family such as CD95/Fas or TRAIL receptors. To evaluate this possibility, we assessed the expression of Fas and its ligand on B-CLL cells, which were cultured in the presence or absence of IS ODN (ODN 2006) or control ODN (ODN 2243) at 5 µg/ml as described before, and then the expression levels of Fas and Fas ligand were determined on days 0, 4, and 7 by FACS analysis. As illustrated in Figure 5A , Fas and Fas ligand were significantly up-regulated in the presence but not in the absence of IS ODN.



View larger version (29K):
[in this window]
[in a new window]
  		Figure 5. Expression of death receptors and their ligands on B-CLL cells is up-regulated by IS ODN. PBMC from subjects with B-CLL or healthy volunteers were obtained and cultured in the presence or absence of 5 µg/ml IS ODN (ODN 2006) or control ODN (ODN 2243) for 4 and 7 days. (A) The expression of Fas ligand (n=5), TRAIL (n=15), CD95/Fas (n=12), TRAIL receptors 1 and 2 (R1 and R2; n=11), and TRAIL receptors 3 and 4 (R3 and R4; n=6) was determined on B-CLL cells by FACS analysis. Relative MFI values as compared with expression on day 0 are shown. No up-regulation of markers was found with control ODN. Error bars indicate SEM. (B) Up-regulation of CD95/Fas on day 4 in response to IS ODN in normal B cells as well as B-CLL cells sensitive to IS ODN-mediated apoptosis versus those that do not undergo apoptosis in response to IS ODN.

 
It is interesting that the IS ODN-mediated up-regulation of Fas was greater in samples sensitive to IS ODN-mediated apoptosis (relative IS ODN survival <1) as compared with samples resistant to IS ODN-mediated apoptosis (relative IS ODN survival >1; Fig. 5B ; *P<0.02). However, normal B cells that proliferate in response to IS ODN also strongly up-regulated CD95/Fas after IS ODN stimulation (Fig. 5B) . IS ODN up-regulated other death receptors of the TNF receptor family including TRAIL receptors 1–4 as well as its ligand TRAIL on B-CLL cells (Fig. 5A) ; however, no correlation was found between up-regulation of these molecules by B-CLL cells and their sensitivity to IS ODN-mediated apoptosis.

To test our hypothesis that death receptors might be involved in IS ODN-mediated apoptosis, we used soluble Fas-Fc or TRAIL receptor 2-Fc fusion proteins to block interaction of Fas with Fas ligand or TRAIL with TRAIL receptors on B-CLL cells, which were sensitive to IS ODN-induced apoptosis and were incubated in the presence or absence of IS ODN at 5 µg/ml and different fusion proteins at 5 µg/ml for 4 days. As illustrated in Figure 6 , IS ODN-induced apoptosis was not blocked by these fusion proteins (Fig. 6) .



View larger version (21K):
[in this window]
[in a new window]
  		Figure 6. Effect of soluble Fas and TRAIL receptor 2 on IS ODN-induced apoptosis of B-CLL cells, which were sensitive to IS ODN-mediated apoptosis from three different subjects and were isolated and cultured in complete medium in the presence or absence of IS ODN (ODN 2006) and fusion proteins consisting of the Fc portion of human Ig and Fas, TRAIL receptor 2, or a control protein at 5 µg/ml. B-CLL cell survival after 4 days incubation was determined as described. Shown are the average percentages of three independent experiments. Error bars indicate SEM.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
IS ODN can induce activation of B cells as indicated by up-regulation of costimulatory and antigen-presenting molecules and induction of proliferation [13 ]. One class of IS ODN, CpG ODN, provides a danger signal through TLR9, one of 10 pattern recognition receptors known to date [17 ]. In humans, TLR9 is expressed almost exclusively in B cells and plasmacytoid DC [16 ]. Another important effect of CpG ODN is the inhibition of apoptosis, particularly of memory B cells. The antiapoptotic and proproliferative effect of CpG ODN on benign B cells enables CpG ODN to trigger rapid B cell expansion in vivo [14 ]. We and others have reported previously that CpG ODN induce phenotypic changes in malignant B cells, which are similar to those seen with benign cells [9 , 10 , 18 ]. In the present study, we report that some of the effects on B-CLL cells of IS ODN, including CpG ODN and non-CpG ODN, are distinct from their effects on benign cells, and IS ODN (and to a lesser degree, non-IS ODN such as ODN 2243) induces sensitivity rather than resistance to apoptosis in most B-CLL samples.

Chromosomal aberrations are among a number of prognostic features (such as serum thymidine kinase, lactate dehydrogenase level, mutational status, ZAP-70 expression, and CD38 expression) known to correlate with B-CLL patient survival, disease progression, and treatment-free interval [2 ]. The most frequent aberration is the 13q14.3 deletion, which is found in up to 50% of patients and is generally associated with a better prognosis than the presence of other aberrations such as 17p deletion, 11q deletion, or trisomy 12. We found samples with 13q deletion, as single aberrations were sensitive to IS ODN-induced apoptosis, and B-CLL cells with other chromosomal aberrations including 17p deletion, 11q deletion, or trisomy 12 showed a more heterogeneous response. In contrast, we found no correlation between IS ODN-induced apoptosis and ZAP-70 expression in B-CLL cells. Given that there is a high concordance between ZAP-70 protein expression and Ig heavy-chain variable region (IgVH) gene mutations in B-CLL [19 ], it is unlikely that mutational status of the IgVH gene plays a role in the IS ODN-mediated effects described above.

In the data outlined above, we found that not only CpG ODN (ODN 2006, ODN 2059) but also ODN lacking the classical CpG motif (ODN 2137 and to a lesser degree, ODN 2243) have effects on B-CLL survival. These results suggest that induction of B-CLL cell apoptosis may depend not only on the TLR9 pathway activated by CpG motifs but also on other factors such as the ODN backbone (PS modification). Consistent with this conclusion is our observation that the level of B-CLL TLR9 expression did not correlate with sensitivity to IS ODN-induced apoptosis, suggesting variations in the expression of this receptor were not (or not alone) responsible for differences in response to IS ODN between B-CLL samples. In this context, it is important to mention that benign B cells also respond to some ODN lacking the CpG motif with changes in phenotype and proliferation.

We do not yet know what factors are responsible for the variable sensitivity of various cytogenetic groups to IS ODN-induced apoptosis. Potential candidates include pathways known to be directly involved in B-CLL growth, survival, and apoptosis, such as phosphatidylinositol-3-kinase (PI-3K), AKT, caspases, or members of the bcl-2 family. A report from Kienle et al. [20 ] suggests that mRNA expression of molecules such as bax, bcl-2, and PI-3K in B-CLL cells varies based on the cytogenetic or the mutational status of B-CLL cells. Ongoing studies are assessing the potential significance of these molecules in IS ODN-induced apoptosis.

Our data demonstrate that caspase activation is involved in the apoptosis-inducing effects of IS ODN in B-CLL cells. The activation of caspase 8 points to a possible involvement of death receptors. Indeed, we found IS ODN induced up-regulation of different members of the TNF receptor family, particularly CD95/Fas and its ligand, suggesting a potential mechanism by which IS ODN increases sensitivity of B-CLL cells to apoptosis. The up-regulation of CD95/Fas by IS ODN was significantly higher in B-CLL cells sensitive to IS ODN-mediated apoptosis. However, we found benign B cells also up-regulate CD95/Fas in response to IS ODN, yet such treatment leads to proliferation and resistance to apoptosis. In our B-CLL samples, IS ODN-mediated apoptosis was not inhibited by blocking Fas ligand or TRAIL using soluble CD95/Fas or TRAIL receptor 2. These data suggest other receptors or heterogeneity in downstream signaling are involved in determining the different response to IS ODN of benign B cells and B-CLL cells of different subgroups.

Additional studies are needed to explore the role death receptor family members play in the ability of IS ODN to induce apoptosis of B-CLL cells. In addition, it is unclear whether the apoptosis-inducing effect of IS ODN in B-CLL cells will have therapeutic value. A clinical trial of ODN 2006 as a single agent in subjects with B-CLL has begun recently, and information related to changes in phenotype, as well as any clinical responses, should provide valuable information in this regard.

In conclusion, a majority of B-CLL samples, particularly those with 13q14.3 deletion as a single aberration, undergoes apoptosis in response to various ODN. This is seen with ODN containing the classic CpG motif but other ODN as well. This is in contrast to the ability of ODN to stimulate proliferation and inhibit apoptosis of benign B cells, which is limited to IS ODN. IS ODN-mediated B-CLL apoptosis depends in part on caspase activation and is accompanied by up-regulation of Fas and Fas ligand. Clinical studies exploring the effect of IS ODN on B-CLL have just begun. Although the possible therapeutic value of these findings remains to be determined, our results provide further evidence for pursuing IS ODN as a potential therapeutic agent in B-CLL and may provide a valuable tool for the investigation of apoptosis pathways in B-CLL.


   ACKNOWLEDGEMENTS
 
This work was supported in part by American Cancer Society Grant IRG-77-004-25 administered through the Holden Comprehensive Cancer Center and National Institutes of Health Grants R01 CA77764 and P50 CA97274-01. We thank Justin Fishbaugh and Gene Hess from the Holden Comprehensive Cancer Center Flow Cytometry Facility for excellent technical assistance and Dr. Shiva Patil from the University of Iowa Cytogenetics Laboratory for generous support with the FISH analysis.

Received June 29, 2004; revised November 8, 2004; accepted November 15, 2004.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. O’Brien, S., Del Giglio, A., Keating, M. (1995) Advances in the biology and treatment of B-cell chronic lymphocytic leukemia Blood 85,307-318[Abstract/Free Full Text]
  2. Dohner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Krober, A., Bullinger, L., Dohner, K., Bentz, M., Lichter, P. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia N. Engl. J. Med. 343,1910-1916[Abstract/Free Full Text]
  3. Van den Hove, L. E., Van Gool, S. W., Vandenberghe, P., Bakkus, M., Thielemans, K., Boogaerts, M. A., Ceuppens, J. L. (1997) CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules Leukemia 11,572-580[CrossRef][Medline]
  4. Donepudi, M., Jovasevic, V. M., Raychaudhuri, P., Mokyr, M. B. (2003) Melphalan-induced up-regulation of B7–1 surface expression on normal splenic B cells Cancer Immunol. Immunother. 52,162-170[Medline]
  5. Wendtner, C. M., Kofler, D. M., Theiss, H. D., Kurzeder, C., Buhmann, R., Schweighofer, C., Perabo, L., Danhauser-Riedl, S., Baumert, J., Hiddemann, W., Hallek, M., Buning, H. (2002) Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors Blood 100,1655-1661[Abstract/Free Full Text]
  6. Chu, P., Deforce, D., Pedersen, I. M., Kim, Y., Kitada, S., Reed, J. C., Kipps, T. J. (2002) Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia Proc. Natl. Acad. Sci. USA 99,3854-3859[Abstract/Free Full Text]
  7. Tretter, T., Schuler, M., Schneller, F., Brass, U., Esswein, M., Aman, M. J., Huber, C., Peschel, C. (1998) Direct cellular interaction with activated CD4(+) T cells overcomes hyporesponsiveness of B-cell chronic lymphocytic leukemia in vitro Cell. Immunol. 189,41-50[CrossRef][Medline]
  8. Anether, G., Marschitz, I., Tinhofer, I., Greil, R. (2002) Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia Blood 99,722-723[Free Full Text]
  9. Jahrsdörfer, B., Hartmann, G., Racila, E., Jackson, W., Mühlenhoff, L., Meinhardt, G., Endres, S., Link, B., Krieg, A., Weiner, G. (2001) CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens J. Leukoc. Biol. 69,81-88[Abstract/Free Full Text]
  10. Jahrsdörfer, B., Jox, R., Muhlenhoff, L., Tschoep, K., Krug, A., Rothenfusser, S., Meinhardt, G., Emmerich, B., Endres, S., Hartmann, G. (2002) Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN J. Leukoc. Biol. 72,83-92[Abstract/Free Full Text]
  11. Decker, T., Schneller, F., Kronschnabl, M., Dechow, T., Lipford, G. B., Wagner, H., Peschel, C. (2000) Immunostimulatory CpG-oligodeoxynucleotides induce functional high-affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype Exp. Hematol. 28,558-568[CrossRef][Medline]
  12. Decker, T., Schneller, F., Sparwasser, T., Tretter, T., Lipford, G. B., Wagner, H., Peschel, C. (2000) Immunostimulatory CpG-oligodeoxynucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells Blood 95,999-1006[Abstract/Free Full Text]
  13. Krieg, A. M., Yi, A. K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., Klinman, D. M. (1995) CpG motifs in bacterial DNA trigger direct B-cell activation Nature 374,546-549[CrossRef][Medline]
  14. Bernasconi, N. L., Traggiai, E., Lanzavecchia, A. (2002) Maintenance of serological memory by polyclonal activation of human memory B cells Science 298,2199-2202[Abstract/Free Full Text]
  15. Hartmann, G., Krug, A., Eigler, A., Moeller, J., Murphy, J., Albrecht, R., Endres, S. (1996) Specific suppression of human tumor necrosis factor-{alpha} synthesis by antisense oligodeoxynucleotides Antisense Nucleic Acid Drug Dev. 6,291-299[Medline]
  16. Hornung, V., Rothenfusser, S., Britsch, S., Krug, A., Jahrsdorfer, B., Giese, T., Endres, S., Hartmann, G. (2002) Quantitative expression of Toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides J. Immunol. 168,4531-4537[Abstract/Free Full Text]
  17. Barton, G. M., Medzhitov, R. (2002) Toll-like receptors and their ligands Curr. Top. Microbiol. Immunol. 270,81-92[Medline]
  18. Decker, T., Peschel, C. (2001) Effect of immunostimulatory CpG-oligodeoxynucleotides in chronic lymphocytic leukemia B cells Leuk. Lymphoma 42,301-307[Medline]
  19. Orchard, J. A., Ibbotson, R. E., Davis, Z., Wiestner, A., Rosenwald, A., Thomas, P. W., Hamblin, T. J., Staudt, L. M., Oscier, D. G. (2004) ZAP-70 expression and prognosis in chronic lymphocytic leukaemia Lancet 363,105-111[CrossRef][Medline]
  20. Kienle, D., Korz, C., Hosch, B., Kroeber, A., Habermann, A., Benner, A., Lichter, P., Doehner, H., Stilgenbauer, S. (2003) Evidence for distinct pathomechanisms in genetic subgroups of CLL by quantitative expression analysis of cell cycle, activation-, and apoptosis-associated genes 45. Annual Meeting of the American Society of Hematology 102,187a-188a



This article has been cited by other articles:


Home page
 BloodHome page
D. Chiron, I. Bekeredjian-Ding, C. Pellat-Deceunynck, R. Bataille, and G. Jego
Toll-like receptors: lessons to learn from normal and malignant human B cells
Blood, September 15, 2008; 112(6): 2205 - 2213.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. Paone, D. Starace, R. Galli, F. Padula, P. De Cesaris, A. Filippini, E. Ziparo, and A. Riccioli
Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-{alpha}-dependent mechanism
Carcinogenesis, July 1, 2008; 29(7): 1334 - 1342.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. Gowda, J. Roda, S.-R. A. Hussain, A. Ramanunni, T. Joshi, S. Schmidt, X. Zhang, A. Lehman, D. Jarjoura, W. E. Carson, et al.
IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro
Blood, May 1, 2008; 111(9): 4723 - 4730.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
P. Secchiero, E. Melloni, M. Tiribelli, A. Gonelli, and G. Zauli
Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells
J. Leukoc. Biol., February 1, 2008; 83(2): 434 - 437.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. P. Leonard, B. K. Link, C. Emmanouilides, S. A. Gregory, D. Weisdorf, J. Andrey, J. Hainsworth, J. A. Sparano, D. E. Tsai, S. Horning, et al.
Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non Hodgkin's Lymphoma
Clin. Cancer Res., October 15, 2007; 13(20): 6168 - 6174.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. Li, W. Song, D. K. Czerwinski, B. Varghese, S. Uematsu, S. Akira, A. M. Krieg, and R. Levy
Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself
J. Immunol., August 15, 2007; 179(4): 2493 - 2500.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Jahrsdorfer, S. E. Blackwell, J. E. Wooldridge, J. Huang, M. W. Andreski, L. S. Jacobus, C. M. Taylor, and G. J. Weiner
B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation
Blood, October 15, 2006; 108(8): 2712 - 2719.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.0604373v1
77/3/378    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jahrsdörfer, B.
Right arrow Articles by Weiner, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jahrsdörfer, B.
Right arrow Articles by Weiner, G. J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS